Hematologic Malignancy
Myeloid Leukemia
CI-CAN-00001251Explore in graph →
Hematologic862 active trials22 approved drugs599 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001251Explore in graph →
Clinical trials
3,530 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (619)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02675478 | Phase 1 Study of Quizartinib | completed | Phase 1 | 17 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Feb 12, 2019 | clinicaltrials |
| NCT01729845 | Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 52 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 7, 2019 | clinicaltrials |
| NCT02296242 | Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 53 | BioMed Valley Discoveries, IncINDUSTRY | 1 | Jan 29, 2019 | clinicaltrials |
| NCT02323607 | Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations | completed | Phase 1 | 13 | Bhavana BhatnagarOTHER | 1 | Jan 25, 2019 | clinicaltrials |
| NCT02086773 | Red Cell Transfusion Goals in Patients With Acute Leukemias | completed | Phase 1 | 90 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 24, 2019 | clinicaltrials |
| NCT01634217 | Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation | completed | Phase 1 | 16 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 18, 2019 | clinicaltrials |
| NCT00718159 | Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia | completed | Phase 1 | 23 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 10, 2019 | clinicaltrials |
| NCT01933906 | Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response | completed | Phase 1 | 12 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT02070458 | Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 30 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 13, 2018 | clinicaltrials |
| NCT00840346 | Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML)(PANOBIDARA) | completed | Phase 1 / Phase 2 | 46 | PETHEMA FoundationOTHER | 1 | Dec 11, 2018 | clinicaltrials |
| NCT00047502 | Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia | completed | Phase 1 | 23 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT01734304 | DC Vaccination for Postremission Therapy in AML | completed | Phase 1 / Phase 2 | 13 | Ludwig-Maximilians - University of MunichOTHER | 1 | Oct 12, 2018 | clinicaltrials |
| NCT01621724 | WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study | completed | Phase 1 / Phase 2 | 7 | Cell Medica LtdINDUSTRY | 1 | Oct 2, 2018 | clinicaltrials |
| NCT02550535 | A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients | completed | Phase 1 / Phase 2 | 3 | Cell Medica LtdINDUSTRY | 3 | Oct 2, 2018 | clinicaltrials |
| NCT01319864 | POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients | completed | Phase 1 | 20 | Seattle Children's HospitalOTHER | 2 | Sep 7, 2018 | clinicaltrials |
| NCT01422603 | Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML) | completed | Phase 1 / Phase 2 | 9 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT01602952 | Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI | completed | Phase 1 / Phase 2 | 85 | Il-Yang Pharm. Co., Ltd.INDUSTRY | 3 | Aug 29, 2018 | clinicaltrials |
| NCT00542971 | Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) | completed | Phase 1 / Phase 2 | 78 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 23, 2018 | clinicaltrials |
| NCT01534260 | Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype | completed | Phase 1 / Phase 2 | 37 | Hamid SayarOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT01484015 | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia | completed | Phase 1 | 70 | Wake Forest University Health SciencesOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT01517035 | Improving Blood Stem Cell Collection and Transplant Procedures | completed | Phase 1 / Phase 2 | 43 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT02226861 | Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation | completed | Phase 1 | 24 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01768897 | CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 67 | Wake Forest University Health SciencesOTHER | 1 | Jul 3, 2018 | clinicaltrials |
| NCT01352650 | Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML) | completed | Phase 1 | 71 | Weill Medical College of Cornell UniversityOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT00890929 | Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 45 | Stanford UniversityOTHER | 1 | Jun 18, 2018 | clinicaltrials |
| NCT02210858 | Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders | completed | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2018 | clinicaltrials |
| NCT02203825 | Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands | completed | Phase 1 | 12 | Celyad Oncology SAINDUSTRY | 1 | Jun 1, 2018 | clinicaltrials |
| NCT00660920 | Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies | completed | Phase 1 | 81 | Ariad PharmaceuticalsINDUSTRY | 1 | May 16, 2018 | clinicaltrials |
| NCT02326584 | A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML | completed | Phase 1 | 116 | Seagen Inc.INDUSTRY | 1 | May 9, 2018 | clinicaltrials |
| NCT01757639 | Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Mar 21, 2018 | clinicaltrials |
| NCT01798901 | AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia | completed | Phase 1 | 13 | Alison WalkerOTHER | 1 | Mar 14, 2018 | clinicaltrials |
| NCT02283190 | 1336GCC: Study of Erwinaze for Treatment of Acute Myeloid Leukemia (AML) | completed | Phase 1 | 5 | Ashkan EmadiOTHER | 1 | Mar 12, 2018 | clinicaltrials |
| NCT00602225 | Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 50 | University of WashingtonOTHER | 1 | Mar 9, 2018 | clinicaltrials |
| NCT01842139 | Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission | completed | Phase 1 | 7 | University of ChicagoOTHER | 1 | Mar 9, 2018 | clinicaltrials |
| NCT00875693 | A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML) | completed | Phase 1 | 47 | Weill Medical College of Cornell UniversityOTHER | 1 | Jan 17, 2018 | clinicaltrials |
| NCT00908167 | Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies | completed | Phase 1 | 44 | St. Jude Children's Research HospitalOTHER | 1 | Jan 12, 2018 | clinicaltrials |
| NCT00854646 | Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) | completed | Phase 1 | 22 | Traws Pharma, Inc.INDUSTRY | 1 | Jan 10, 2018 | clinicaltrials |
| NCT00541866 | Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans | completed | Phase 1 / Phase 2 | 110 | Sunesis PharmaceuticalsINDUSTRY | 1 | Jan 9, 2018 | clinicaltrials |
| NCT01902329 | A Safety Study of SGN-CD33A in AML Patients | completed | Phase 1 | 195 | Seagen Inc.INDUSTRY | 1 | Jan 5, 2018 | clinicaltrials |
| NCT00303667 | Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 50 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT02308761 | A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome | completed | Phase 1 | 26 | Hoffmann-La RocheINDUSTRY | 1 | Dec 11, 2017 | clinicaltrials |
| NCT02093403 | Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 25 | Bhavana BhatnagarOTHER | 1 | Dec 8, 2017 | clinicaltrials |
| NCT01110473 | ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies | completed | Phase 1 | 52 | AbbVie (prior sponsor, Abbott)INDUSTRY | 1 | Nov 20, 2017 | clinicaltrials |
| NCT00466895 | Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia. | completed | Phase 1 | 37 | Leslie AndritsosOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT01380756 | Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia | completed | Phase 1 | 35 | AmgenINDUSTRY | 1 | Nov 6, 2017 | clinicaltrials |
| NCT02270788 | Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies | completed | Phase 1 | 10 | St. Jude Children's Research HospitalOTHER | 1 | Oct 3, 2017 | clinicaltrials |
| NCT01449058 | A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors | completed | Phase 1 | 139 | Array BioPharmaINDUSTRY | 7 | Oct 2, 2017 | clinicaltrials |
| NCT02544438 | Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia(BSTPHASE1-01) | completed | Phase 1 / Phase 2 | 20 | BioSight Ltd.INDUSTRY | 1 | Sep 27, 2017 | clinicaltrials |
| NCT01254578 | Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers | completed | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2017 | clinicaltrials |
| NCT01249430 | Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Feb 12, 2019source: clinicaltrials